Welcome to our dedicated page for Global Medical SEC filings (Ticker: GMRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Global Medical REIT Inc. (GMRE) SEC filings page provides direct access to the company’s regulatory disclosures, along with AI-assisted summaries to help interpret complex documents. As a net-lease medical real estate investment trust, GMRE files annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K that describe its healthcare real estate portfolio, lease structures, financing arrangements and governance matters.
In these filings, Global Medical REIT details its rental revenue, net income or loss, Funds From Operations (FFO), Adjusted Funds From Operations (AFFO), Funds Available for Distribution (FAD), Earnings Before Interest, Taxes, Depreciation and Amortization for Real Estate (EBITDAre and Adjusted EBITDAre), Net Operating Income (NOI), cash NOI and same-store cash NOI. The company also discloses portfolio occupancy, leasable square footage, annualized base rent, lease expiration schedules and the mix of outpatient medical buildings, inpatient rehabilitation facilities, hospitals and other medical real estate. Our AI tools highlight how these metrics are calculated and what they imply for operating performance and leverage.
Recent Form 8-K filings for GMRE include disclosures about amendments and restatements of its credit facility, including extended maturities for its revolver and term loans and the removal of a SOFR credit spread adjustment, as well as the use of forward-starting interest rate swaps to hedge term loan exposure. Other 8-Ks describe the authorization and mechanics of a one-for-five reverse stock split, the approval of a common stock repurchase program, the appointment of a new Chief Executive Officer and President, and the planned retirement of a long-serving independent director.
Filings also cover capital markets transactions such as the underwriting agreement for GMRE’s 8.00% Series B Cumulative Redeemable Preferred Stock and related Articles Supplementary and partnership agreement amendments. Through this page, users can review Forms 3, 4 and 5 for insider ownership and trading activity, as well as proxy materials that discuss executive compensation and board structure when available. Real-time updates from the SEC’s EDGAR system, combined with AI-generated explanations, make it easier to understand how Global Medical REIT’s filings relate to its portfolio strategy, capital structure and dividend practices.
Global Medical REIT Inc. (GMRE) furnished its Third Quarter 2025 results materials. On November 4, 2025, the company announced its financial position as of September 30, 2025 and operating results for the three and nine months ended September 30, 2025. The earnings release (Exhibit 99.1) and earnings supplemental (Exhibit 99.2) were posted to its website and furnished with this report.
The materials are furnished, not filed, under the Exchange Act and are not subject to Section 18 liabilities, nor incorporated by reference into other filings.
Global Medical REIT Inc. amended its credit facilities to extend maturities and reprice a spread adjustment. The $400M revolver maturity is extended to
Global Medical REIT Inc. director Matthew Cypher purchased 1,350 shares of the company's common stock on 08/26/2025 at a price of $7.3781 per share. After the transaction he beneficially owns 1,350 shares, held directly. The Form 4 was signed by an attorney-in-fact, Jamie Barber, on the same date.
Jamie Allen Barber, who serves as General Counsel and Secretary and is identified as a director, reported the sale of 130,000 shares of Global Medical REIT Inc. (GMRE) on 08/15/2025. The Form 4 shows the shares were sold at a weighted average price of $6.6236 (individual trade prices ranged from $6.50 to $6.74). Following the reported transactions the filing indicates 0 shares beneficially owned by the reporting person. The form was signed on 08/18/2025 and was filed by one reporting person.
Global Medical REIT Inc. (GMRE) director and CEO Mark O. Decker Jr. reported purchases of common stock on 08/15/2025: 13,871 shares at $6.84 (direct), and 17,023 shares at $6.87 (indirect via spouse). After these transactions he beneficially owned 173,871 shares directly and 190,894 shares indirectly.
Global Medical REIT Inc. (GMRE) Form 144: This notice reports a proposed sale of 130,000 common shares, with an aggregate market value of $878,000.00. The shares were acquired on 08/07/2025 as a stock award from the issuer and paid as compensation. The filer lists Fidelity Brokerage Services LLC (245 Summer Street, Boston MA) as the broker and identifies an approximate sale date of 08/15/2025 on the NYSE. The issuer's reported number of shares outstanding is 66,878,728. The filing states there were no securities sold in the past three months by the person for whose account the securities will be sold. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Jamie Barber, who serves as General Counsel and Secretary and is a director of Global Medical REIT Inc. (GMRE), converted 130,000 long-term incentive plan units (LTIP Units) in the operating partnership into OP Units and had those OP Units redeemed for an equal number of the issuer's common shares. As a result, Barber directly beneficially owns 130,000 shares of GMRE common stock following the transaction. The filing states LTIP Units were issued under the 2016 Equity Incentive Plan and have no expiration date, and OP Units may be redeemed for cash or, at the issuer's election, for one-for-one shares of common stock.
GMRE’s Q2 2025 10-Q shows modest top-line growth offset by higher financing costs. Rental revenue rose 10.7% YoY to $37.9 m, lifting total revenue to $38.0 m. Operating expense inflation (+13%) and an 15% jump in interest expense limited operating income to $0.4 m (vs. $1.4 m LY). Net income turned positive at $0.6 m, yet after $1.5 m preferred dividends common shareholders posted a $0.8 m loss (-$0.01/sh).
Balance sheet leverage increased. Net real-estate investment grew $42 m to $1.20 b after acquiring five facilities for $79.7 m and selling three for $9.1 m gains. Credit-facility borrowings expanded $67 m to $699 m, pushing total liabilities to $772 m (+10%). Equity fell 6% to $525 m, driven by dividend distributions and an $8.2 m OCI hit from falling swap values. Cash flow from operations covered common and preferred dividends ($34.4 m OCF vs. $33.4 m payouts). Management flags $24.6 m of committed cap-ex (≈$12.6 m in next 12 mo).
Key trends: 1) revenue growth from acquisitions continues; 2) elevated debt and rising SOFR expose earnings to rate risk despite hedges; 3) dividend remains higher than GAAP earnings but covered by FFO proxy cash flow; 4) active capital recycling—three small Q1-Q2 sales and a 12.5% JV stake launched in late-2024.
FAQ
What is the current stock price of Global Medical (GMRE)?
What is the market cap of Global Medical (GMRE)?
